...
首页> 外文期刊>Neurology: Official Journal of the American Academy of Neurology >Assessing autonomic dysfunction in early diabetic neuropathy: the Survey of Autonomic Symptoms.
【24h】

Assessing autonomic dysfunction in early diabetic neuropathy: the Survey of Autonomic Symptoms.

机译:评估在早期糖尿病自主神经功能失调神经病变:自主症状的调查。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: Autonomic symptoms may occur frequently in diabetic and other neuropathies. There is a need to develop a simple instrument to measure autonomic symptoms in subjects with neuropathy and to test the validity of the instrument. METHODS: The Survey of Autonomic Symptoms (SAS) consists of 11 items in women and 12 in men. Each item is rated by an impact score ranging from 1 (least severe) to 5 (most severe). The SAS was tested in observational studies and compared to a previously validated autonomic scale, the Autonomic Symptom Profile (ASP), and to a series of autonomic tests. RESULTS: The SAS was tested in 30 healthy controls and 62 subjects with neuropathy and impaired glucose tolerance or newly diagnosed diabetes. An increased SAS score was associated with the previously validated ASP (rank order correlation=0.68; p<0.0001) and with quantitative measures of autonomic function: a reduced quantitative sudomotor axon reflex test sweat volume (0.31; p<0.05) and an abnormal 30:15 ratio (0.53; p<0.01). The SAS shows a high sensitivity and specificity (area under the receiver operating characteristic curve 0.828) that compares favorably with the ASP. The SAS scale domains had a good internal consistency and reliability (Cronbach alpha=0.76). The SAS symptom score was increased in neuropathy (95% confidence interval [CI] 2.99-4.14) compared to control (95% CI 0.58-1.69; p<0.0001) subjects. CONCLUSIONS: The SAS is a new, valid, easily administered instrument to measure autonomic symptoms in early diabetic neuropathy and would be of value in assessing neuropathic autonomic symptoms in clinical trials and epidemiologic studies.
机译:目的:自主症状可能经常发生在糖尿病和其他疾病。需要开发一个简单的测量工具自主神经病变症状在主题和测试仪器的有效性。方法:自主症状的调查(SAS)包括在女性和男性12 11项。项被分数从1产生影响(严重的)到5(最严重)。观察性研究和比较测试之前验证自主规模,自主症状概要(ASP)和系列自主测试。在30名健康对照组和62例神经病变和葡萄糖耐量新诊断糖尿病。与先前有关验证ASP吗(排序相关= 0.68;定量措施的自主功能:a减少量化催汗的轴突反射测试汗水卷(0.31;比(0.53;敏感性和特异性(面积接受者操作特性曲线0.828)它比ASP。域有一个良好的内部一致性和规模可靠性(克伦巴赫α= 0.76)。神经病变症状分数增加(95%可信区间(CI)相比,2.99 - -4.14)控制(95% CI 0.58 - -1.69;结论:sa是一种新的、有效的仪器测量自主管理在早期糖尿病神经病变和症状有价值的评估神经性自主在临床试验和流行病学症状研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号